NRX Pharmaceuticals, Inc. Logo

NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | US

Overview

Corporate Details

ISIN(s):
US0894821034 (+2 more)
LEI:
Country:
United States of America
Address:
1201 ORANGE STREET, 19801 WILMINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea 011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye GENIL
Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark GMAB
GENMAB A/S Logo
Develops innovative antibody therapeutics for cancer and other serious diseases.
United States of America GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea 225220

Talk to a Data Expert

Have a question? We'll get back to you promptly.